Because it is important: White House officials had warned that the initial supply of Johnson & Johnson vaccine would be limited due to production problems, although the company has said it will honor its agreement to supply the United States with 100 million doses by the end of June.
“We are confident in our plans to deliver 100 million single dose vaccines to the United States during the first half of 2021, and we continue to partner with the US government to explore all options to accelerate delivery,” Nettles will say. .
The vaccine is 66 percent effective against the virus overall, but was only 57 percent effective in a trial in South Africa, where a troublesome strain, B.1.315, has spread widely. That strain has been reported in 10 US states.
Whats Next: The House panel will also hear from executives at Pfizer, Moderna, AstraZeneca and Novavax on the ways that major vaccine manufacturers are increasing production to meet the nation’s vaccine demands.
Pfizer and Moderna have each committed to 300 million doses this year.